SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

ANTIEMETIC/ANTIVERTIGO DRUGS

Drug Requested: (Check below the drug that applies)

PREFERRED MEDICATIONS (*PREFERRED Dronabinol and Diclegis Require Prior Authorization)**		
❑ **Diclegis®** (doxylamine succinate/vitamin B6) ***	❑ **ondansetron ODT (4mg, 8mg)/tab/soln**	❑ **meclizine (OTC, Rx)**
❑ **metoclopramide (tab/soln/vial)**	❑ **Phenadoz® supp (AG) (members over 2 years of age)**	❑ **Prochlorperazine tab**
❑ **promethazine (AG) (members over 2 years of age)**	❑ **dronabinol capsule*** **	

All Non-Preferred Medications Require Prior Authorization			
❑ **Akynzeo®**	❑ **Aloxi®**	❑ **Antivert®**	❑ **Aponvie™**
❑ **aprepitant capsule/pack**	❑ **Barhemsys®**	❑ **Bonjesta®**	❑ **Cesamet®**
❑ **Cinvanti™**	❑ **Compazine® supp/tab**	❑ **Compro®**	❑ **dimenhydrinate tab, vial**
❑ **Emend® Bi Pak**	❑ **Emend® susp**	❑ **Emend® Tri-fold pack**	❑ **Focinvez™**
❑ **Fosaprepitant vial**	❑ **granisetron**	❑ **Kytril®**	❑ **Marinol®**
❑ **metoclopramide ODT**	❑ **ondansetron 16mg ODT**	❑ **palonosetron (generic Aloxi®)**	❑ **prochlorperazine supp, vial**
❑ **promethazine 50mg supp, vial, ampule**	❑ **Reglan®**	❑ **Sancuso® patch**	❑ **scopolamine (generic Transderm-Scop®)**
❑ **Sustol®**	❑ **Syndros™**	❑ **Transderm-Scop®**	❑ **trimethobenzamide**
❑ **Varubi®**	❑ **Vistaril®**	❑ **Zofran® ODT/soln/tab**	

(Continued on next page)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

DIAGNOSIS AND CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

1. Diagnosis of severe, chemotherapy induced nausea and vomiting? ❑ Yes ❑ No
2. If diagnosis is AIDS-related wasting, has member tried and failed megestrol acetate oral suspension **OR** has a contraindication, intolerance, drug-drug interaction? ❑ Yes ❑ No
3. Nausea or vomiting related to radiation therapy, moderate-to-highly emetogenic chemotherapy, or post-operative nausea and vomiting? ❑ Yes ❑ No
4. Member has tried and failed therapeutic doses of, or has adverse effects or contraindications to **TWO (2)** different conventional antiemetics **(e.g., promethazine, prochlorperazine, meclizine, metoclopramide, dexamethasone, etc.)**? ❑ Yes ❑ No
5. Member has hyperemesis (pregnancy-related nausea/vomiting)? ❑ Yes ❑ No
6. **Bonjesta®/Diclegis®:** length of approval, Estimated Delivery Date (EDD)

   Member must be pregnant and at least 18 years of age ❑ Yes ❑ No

   Estimated Delivery Date: _____

   If requesting **Bonjesta®**, member must have tried and failed **Diclegis®** ❑ Yes ❑ No

(Continued on next page)

7. Does the member have diabetic gastroparesis? If yes, list why oral metoclopramide cannot be used.
   Yes ❑ No

   _____

   _____

8. For **ondansetron 16mg ODT**:
   Has the member tried and failed or been intolerant to ondansetron 8 mg ODT? Yes ❑ No
9. Provide clinical evidence that the **Preferred** drug(s) will not provide adequate benefit and list pharmaceutical drugs attempted and outcome.

   _____

   _____

   _____

   _____

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****